|
|
|
|
|
|
|
|
abstract
Introduction:
Chemotherapy-induced peripheral neuropathies (CIPN) are a dose-limiting
adverse effect of certain anticancer drugs (platinum salts, vinca
alkaloids, taxanes, bortezomib, thalidomide, epothilones, eribulin).
CIPN are mainly responsible for sensory disturbances and are associated
with a decrease in quality of life. After the end of chemotherapy, CIPN
can last for several months and even years. Unfortunately, recent
meta-analyses of clinical trials have demonstrated that there is no
univocal gold standard for the prevention and treatment of CIPN.
Expert opinion:
To date, based on meta-analyses of clinical trials, no drug can be
proposed as a gold standard to prevent or treat CIPN. Consequently,
there is a strong discrepancy between the optimistic results of animal
studies and the poor outcomes of clinical trials. Pain assessment in
preclinical and clinical studies is probably not the best outcome
measurement tool and all these studies should include composite outcomes
including the full complexity of CIPN symptoms, such as positive
symptoms (pain, paresthesia, and dysesthesia) and negative ones
(numbness).
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.